Samsung Asset Management (new York) Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Samsung Asset Management (new York) reduced its stake in Merck & Co. by 42.69% during the most recent quarter end. The investment management company now holds a total of 64,850 shares of Merck & Co. which is valued at $4,076,471 after selling 48,300 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Merck & Co. makes up approximately 2.97% of Samsung Asset Management (new York)’s portfolio.

Other Hedge Funds, Including , Signature Estate Investment Advisors added MRK to its portfolio by purchasing 2,700 company shares during the most recent quarter which is valued at $171,801. Merck & Co. makes up approx 0.03% of Signature Estate Investment Advisors’s portfolio.Gratus Capital reduced its stake in MRK by selling 2,454 shares or 34.74% in the most recent quarter. The Hedge Fund company now holds 4,609 shares of MRK which is valued at $265,709. Merck & Co. makes up approx 0.04% of Gratus Capital’s portfolio. Polaris Greystone Financial Group added MRK to its portfolio by purchasing 265,818 company shares during the most recent quarter which is valued at $15,324,408. Merck & Co. makes up approx 2.33% of Polaris Greystone Financial Group’s portfolio.Investment Partners Ltd Oh Adv reduced its stake in MRK by selling 12,528 shares or 41.52% in the most recent quarter. The Hedge Fund company now holds 17,645 shares of MRK which is valued at $1,050,760. Merck & Co. makes up approx 1.03% of Investment Partners Ltd Oh Adv’s portfolio.

Merck & Co. opened for trading at $63.03 and hit $63.43 on the upside on Wednesday, eventually ending the session at $63.29, with a gain of 0.40% or 0.25 points. The heightened volatility saw the trading volume jump to 82,71,531 shares. Company has a market cap of $175,010 M.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.

Many Wall Street Analysts have commented on Merck & Co.. Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *